The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Belzutifan for Renal Cell Carcinoma in von Hippel–Lindau Disease
Open accessAbstract
BACKGROUND: gene inactivation and constitutive activation of the transcription factor hypoxia-inducible factor 2α (HIF-2α). METHODS: In this phase 2, open-label, single-group trial, we investigated the efficacy and safety of the HIF-2α inhibitor belzutifan (MK-6482, previously called PT2977), administered orally at a dose of 120 mg daily, in patients with renal cell carcinoma associated with VHL disease. The primary end point was objective response (complete or partial response) as measured according to the Response Evaluation Criteria in Solid Tumors, version 1.1, by an independent central radiology review committee. We also assessed responses to belzutifan in patients with non-renal cell carcinoma neoplasms and the safety of belzutifan. RESULTS: After a median follow-up of 21.8 months (range, 20.2 to 30.1), the percentage of patients with renal cell carcinoma who had an objective response was 49% (95% confidence interval, 36 to 62). Responses were also observed in patients with pancreatic lesions (47 of 61 patients [77%]) and central nervous system hemangioblastomas (15 of 50 patients [30%]). Among the 16 eyes that could be evaluated in 12 patients with retinal hemangioblastomas at baseline, all (100%) were graded as showing improvement. The most common adverse events were anemia (in 90% of the patients) and fatigue (in 66%). Seven patients discontinued treatment: four patients voluntarily discontinued, one discontinued owing to a treatment-related adverse event (grade 1 dizziness), one discontinued because of disease progression as assessed by the investigator, and one patient died (of acute toxic effects of fentanyl). CONCLUSIONS: Belzutifan was associated with predominantly grade 1 and 2 adverse events and showed activity in patients with renal cell carcinomas and non-renal cell carcinoma neoplasms associated with VHL disease. (Funded by Merck Sharp and Dohme and others; MK-6482-004 ClinicalTrials.gov number, NCT03401788.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“PT2977/belzutifan was recently approved by the FDA for the treatment of RCC in patients with von Hippel-Lindau syndrome (47, 48).”
From HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy (2022) · cites this paper as [48]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The most frequent on-target toxicity with HIF-2 inhibitors (PT2385; belzutifan) is anemia from suppression of renal/hepatic erythropoietin.”
From HIF inhibition: Current strategies and clinical challenges (2026) · cites this paper as [421]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Anemia occurred commonly in early trials and, during prolonged belzutifan therapy, occasionally required transfusion or erythropoiesis-stimulating agents, hence the need for routine hematological monitoring [37,412,421].”
From HIF inhibition: Current strategies and clinical challenges (2026) · cites this paper as [421]
In the citing paper
“VHL gene mutations lead to the stability of HIF subunits and the constitutive activation of HIF‐mediated transcriptional pathways in patients with VHL, causing the progression of renal cell carcinoma.”
From Hypoxia signaling in cancer: Implications for therapeutic interventions (2023) · cites this paper as [24]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
von Hippel–Lindau disease: A clinical and scientific review
Maher, E. R., Neumann, H. P. H., & Richard, S. (2011) · European Journal of Human Genetics · doi:10.1038/ejhg.2010.175 · Cited by 744
Targeting renal cell carcinoma with a HIF-2 antagonist
Chen, W., Hill, H., Christie, A., Kim, M. S., Holloman, E., Pavia-Jimenez, A., Homayoun, F., Ma, Y., Patel, N., Yell, P., et al. (2016) · Nature · doi:10.1038/nature19796 · Cited by 709
Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo
Rankin, E. B., Biju, M. P., Liu, Q., Unger, T. L., Rha, J., Johnson, R. S., Simon, M. C., Keith, B., & Haase, V. H. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30117 · Cited by 596
Targeting the HIF2–VEGF axis in renal cell carcinoma
Choueiri, T. K., & Kaelin, W. G. (2020) · Nature Medicine · doi:10.1038/s41591-020-1093-z · Cited by 477 · cited 1×
“Upper respiratory tract infection 11 (18) 4 (7) 7 (11) 0”
On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models
Cho, H., Du, X., Rizzi, J. P., Liberzon, E., Chakraborty, A. A., Gao, W., Carvo, I., Signoretti, S., Bruick, R. K., Josey, J. A., et al. (2016) · Nature · doi:10.1038/nature19795 · Cited by 451 · cited 1×
“Alanine aminotransferase level increase 10 (16) 10 (16) 0 0”
BackgroundCourtney, K. D., Infante, J. R., Lam, E. T., Figlin, R. A., Rini, B. I., Brugarolas, J., Zojwalla, N. J., Lowe, A. M., Wang, K., Wallace, E. M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.2627 · Cited by 393
Choueiri, T. K., Bauer, T. M., Papadopoulos, K. P., Plimack, E. R., Merchan, J. R., McDermott, D. F., Michaelson, M. D., Appleman, L. J., Thamake, S., Perini, R. F., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01324-7 · Cited by 305 · cited 1×
“Upper respiratory tract infection 11 (18) 4 (7) 7 (11) 0”
Self-citationPharmacologic Targeting of Hypoxia-Inducible Factors
Semenza, G. L. (2019) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010818-021637 · Cited by 288
HIF-2α regulates murine hematopoietic development in an erythropoietin-dependent manner
Scortegagna, M., Ding, K., Zhang, Q., Oktay, Y., Bennett, M. J., Bennett, M., Shelton, J. M., Richardson, J. A., Moe, O. W., & Garcia, J. A. (2004) · Blood · doi:10.1182/blood-2004-05-1695 · Cited by 237
Courtney, K. D., Ma, Y., Diaz de Leon, A., Christie, A., Xie, Z., Woolford, L., Singla, N., Joyce, A., Hill, H., Madhuranthakam, A. J., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1459 · Cited by 188
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 717
Precision Oncology: Current Landscape, Emerging Trends, Challenges, and Future Perspectives
Qiao, D., Wang, R. C., & Wang, Z. (2025) · Cells · doi:10.3390/cells14221804 · Cited by 39
The emerging landscape of neo/adjuvant immunotherapy in renal cell carcinoma
Dibajnia, P., Cardenas, L. M., & Lalani, A. A. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2178217 · Cited by 29
“Inhibition of this pathway with belzutifan has been demonstrated in a phase II trial to have activity against von Hippel-Lindau associated RCC.(64) Litespark-022 (NCT05239728) is a phase III trial that aims to examine the role of adjuvant belzultifan and pembrolizumab in patients with RCC at intermediate-high or high-…”
MethodDomchek, S. M., & Vonderheide, R. H. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0015 · Cited by 32
Tumorigenesis Mechanisms Found in Hereditary Renal Cell Carcinoma: A Review
Webster, B. R., Gopal, N., & Ball, M. W. (2022) · Genes · doi:10.3390/genes13112122 · Cited by 28
“In addition, responses were seen for 77% of pancreatic lesions, 30% of CNS hemangioblastomas and 100% of retinal lesions [69].”
BackgroundCancer Therapy and Exercise Intolerance: The Heart Is But a Part
Dillon, H. T., Foulkes, S., Baik, A. H., Scott, J. M., Touyz, R. M., Herrmann, J., Haykowsky, M. J., Gerche, A. L., & Howden, E. J. (2024) · JACC CardioOncology · doi:10.1016/j.jaccao.2024.04.006 · Cited by 32
Iacovelli, R., Ciccarese, C., Procopio, G., Astore, S., Cannella, M. A., Maratta, M. G., Rizzo, M., Verzoni, E., Porta, C., & Tortora, G. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102379 · Cited by 25
Celada, L., Cubiella, T., San‐Juan‐Guardado, J., Gutiérrez, G., Beiguela, B., Rodríguez, R. Q., Poch, M., Astudillo, A., Grijalba, A., Sobrino, P. S., et al. (2022) · The Journal of Pathology · doi:10.1002/path.6026 · Cited by 30
“The TCGA cohort includes tumors with genetic alterations affecting other genes involved in oxygen sensing, such as inactivating mutations of VHL or activating mutations of EPAS1.”
BackgroundInfluentialSynthetic Approaches to the New Drugs Approved During 2021
McInturff, E. L., France, S. P., Leverett, C. A., Flick, A. C., Lindsey, E. A., Berritt, S., Carney, D. W., DeForest, J. C., Ding, H. X., Fink, S. J., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00501 · Cited by 26
Semenza, G. L. (2023) · Stem Cells Translational Medicine · doi:10.1093/stcltm/szad061 · Cited by 26
“…the HIF-2-selective inhibitor Belzutifan has been approved for the treatment of renal cell carcinoma in patients with von Hippel-Lindau syndrome, 74 but the studies summarized here suggest this drug will not be effective in blocking hypoxia-induced BCSC specification, which appears to be…”
BackgroundEid, M., Foukal, J., Sochorová, D., Tuček, Š., Starý, K., Kala, Z., Mayer, J., Němeček, R., Trna, J., & Kunovský, L. (2023) · Cancer Medicine · doi:10.1002/cam4.6010 · Cited by 26
Consensus Guidelines for Ocular Surveillance of von Hippel-Lindau Disease
Daniels, A. B., Chang, E., Chew, E. Y., Gombos, D. S., Gorin, M. B., Shields, C. L., & Wiley, H. E. (2023) · Ophthalmology · doi:10.1016/j.ophtha.2023.12.014 · Cited by 25
Crosstalk between hypoxia-induced pyroptosis and immune escape in cancer: From mechanisms to therapy
Meybodi, S. M., Ejlalidiz, M., Manshadi, M. R., Raeisi, M., Zarin, M., Kalhor, Z., Saberiyan, M., & Hamblin, M. R. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104340 · Cited by 24
E-box binding transcription factors in cancer
Pan, Y., van der Watt, P. J., & Kay, S. A. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1223208 · Cited by 24
Novel Approaches with HIF-2α Targeted Therapies in Metastatic Renal Cell Carcinoma
Nguyen, C. B., Oh, E., Bahar, P., Vaishampayan, U. N., Else, T., & Alva, A. S. (2024) · Cancers · doi:10.3390/cancers16030601 · Cited by 26
“In the phase 2 MK-6482-004 trial, patients with a confirmed pathogenic germline variant in VHL and localized RCC received an oral belzutifan dose of 120 milligrams (mg) daily [16].”
MethodSelf-citationBrugarolas, J., Obara, G., Beckermann, K. E., Rini, B., Lam, E. T., Hamilton, J., Schluep, T., Yi, M., Wong, S., Mao, Z. L., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3029 · Cited by 25
“PT2977 (belzutifan) is FDA approved for patients with VHL disease (22) and was recently approved for patients with advanced ccRCC.”
BackgroundFountzilas, E., Tsimberidou, A. M., Vo, H. H., & Kurzrock, R. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102703 · Cited by 26
Emerging innovative treatment strategies for advanced clear cell renal cell carcinoma
Choi, S. H., Chen, Y., Panian, J. A., Yuen, K., & McKay, R. R. (2024) · The Oncologist · doi:10.1093/oncolo/oyae276 · Cited by 27
Molecular mechanisms of resistance to tyrosine kinase inhibitor in clear cell renal cell carcinoma
Sekino, Y., Teishima, J., Liang, G., & Hinata, N. (2022) · International Journal of Urology · doi:10.1111/iju.15042 · Cited by 26
Neurological applications of belzutifan in von Hippel-Lindau disease
Zhang, Y., Nguyen, C. C., Zhang, N., Fink, N. S., John, J. D., Venkatesh, O., Roe, J., Hoffman, S. C., Lesniak, M. S., Wolinsky, J., et al. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac234 · Cited by 24
Guo, X., Song, J., Liu, M., Ou, X., & Guo, Y. (2024) · Cancer Biology & Therapy · doi:10.1080/15384047.2024.2356831 · Cited by 24
Yang, H., Chen, R., Zheng, X., Luo, Y., Yao, M., Ke, F., Guo, X., Liu, X., & Liu, Q. (2025) · Cells · doi:10.3390/cells14100693 · Cited by 24
“For example, the deletion of VHL leads to sustained activation of HIF-2 α in ccRCC, which may serve as the molecular basis for inhibiting the compensatory role of CA XII [103,104].”
HIF-2α expression and metabolic signaling require ACSS2 in clear cell renal cell carcinoma
Bacigalupa, Z. A., Arner, E. N., Vlach, L. M., Wolf, M. M., Brown, W. A., Krystofiak, E., Ye, X., Hongo, R. A., Landis, M. D., Amason, E. K., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci164249 · Cited by 23
“Recent work has confirmed this model through the development of a HIF-2 α –specific transcriptional inhibitor for treatment of VHL -associated RCCs, which has gained FDA approval (8).”
Self-citationNext Wave of Targets in the Treatment of Advanced Renal Cell Carcinoma
Cardenas, L. M., Deluce, J. E., Khan, S., Gulam, O., Vareki, S. M., Fernandes, R., & Lalani, A. A. (2022) · Current Oncology · doi:10.3390/curroncol29080429 · Cited by 23
“toxicities were anemia (any grade in 90%, grade 3 in 8% of patients) and fatigue (any grade in 66%, grade 3 in 5%) [37].”
BackgroundFunctional crosstalk between chromatin and hypoxia signalling
Collier, H., Albanese, A., Kwok, C.-S., Kou, J., & Rocha, S. (2023) · Cellular Signalling · doi:10.1016/j.cellsig.2023.110660 · Cited by 23
Targeting HIF-2 Alpha in Renal Cell Carcinoma
Ahmed, R., & Ornstein, M. C. (2023) · Current Treatment Options in Oncology · doi:10.1007/s11864-023-01106-y · Cited by 22
Zhang, X., Zhang, M., Sun, H., Wang, X., Wang, X., Sheng, W., & Xu, M. (2024) · Journal of Advanced Research · doi:10.1016/j.jare.2024.01.033 · Cited by 22
Kim, I.-H., & Lee, H. J. (2022) · Biomedicines · doi:10.3390/biomedicines10020251 · Cited by 22
Tacelli, M., Gentiluomo, M., Biamonte, P., Castano, J. P., Berković, M. C., Cives, M., Kapitanović, S., Marinoni, I., Marinović, S., Nikas, I. P., et al. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.03.005 · Cited by 23
Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell Carcinoma
Choueiri, T. K., Motzer, R. J., Karam, J. A., Yip, W., Suárez, C., Ye, D., He, Z., Caglevic, C., Ferguson, T., Chang, Y., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2518245 · Cited by 23
The road to systemic therapy in von Hippel-Lindau (VHL) disease: Are we there yet?
Shepherd, S. T. C., Drake, W. M., & Turajlic, S. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.12.011 · Cited by 21
Lipids as Targets for Renal Cell Carcinoma Therapy
Tanturovska, B. S., Manaila, R., Fabbro, D., & Huwiler, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043272 · Cited by 22
“The most common adverse event was anemia occurring in 90% of the patients [215].”
BackgroundHereditary Renal Cancer Syndromes
Yanus, G. A., Kuligina, E. S., & Имянитов, Е. Н. (2024) · Medical Sciences · doi:10.3390/medsci12010012 · Cited by 25
“Belzutifan also demonstrated significant activity against hemangioblastomas and pancreatic lesions, which were observed among the patients included in the study [96].”
BackgroundA year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021
Kayki‐Mutlu, G., Aksoyalp, Z. Ş., Wojnowski, L., & Michel, M. C. (2022) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-022-02250-2 · Cited by 22
Targeting HIF-2α and anemia: A therapeutic breakthrough for clear-cell renal cell carcinoma
Rioja, P., Rey-Cárdenas, M., & de Velasco, G. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102801 · Cited by 21
Belzutifan: a novel therapy for von Hippel–Lindau disease
Zhou, J., & Gong, K. (2022) · Nature Reviews Nephrology · doi:10.1038/s41581-022-00544-5 · Cited by 22
Exposure–response analyses of cabozantinib in patients with metastatic renal cell cancer
Krens, S. D., van Erp, N. P., Groenland, S. L., Moes, D. J. A. R., Mulder, S. F., Desar, I. M. E., van der Hulle, T., Steeghs, N., & van Herpen, C. M. L. (2022) · BMC Cancer · doi:10.1186/s12885-022-09338-1 · Cited by 20
Primary cilia: Structure, dynamics, and roles in cancer cells and tumor microenvironment
Guan, Y., Zhang, C., Zhang, H., Wei, W., Yue, W., Zhao, W., & Zhang, D. (2023) · Journal of Cellular Physiology · doi:10.1002/jcp.31092 · Cited by 21
“To date, belzutifan, an inhibitor of HIF‐2α, demonstrated excellent efficacy in cancers linked to VHL disease and received US Food and Drug Administration approval for the therapy associated with VHL‐related cancers (Deeks, 2021; Jonasch et al., 2021).”
Oral Hypoxia-Inducible Factor 2α Inhibitor Belzutifan in Ocular von Hippel-Lindau Disease
Wiley, H. E., Srinivasan, R., Maranchie, J. K., Chhablani, J. K., Iversen, A. B. B., Kruse, A., Jonasch, E. W., Gombos, D. S., Else, T., Demirci, H., et al. (2024) · Ophthalmology · doi:10.1016/j.ophtha.2024.05.024 · Cited by 20
Self-citationYou, M., Fu, M., Shen, Z., Feng, Y., Zhang, L., Zhu, X., Zhuang, Z., Mao, Y. Q., & Hua, W. (2024) · OncoImmunology · doi:10.1080/2162402x.2024.2356942 · Cited by 20
“…for VHL syndrome-associated renal clear cell carcinoma and other tumors, may offer a viable option for the prevention and treatment of LCBM. 53 Recently, Belzutifan has been approved by the FDA for previously treated advanced renal clear cell carcinoma, indicating that the HIF-2α pathway…”
BackgroundNavigating the Current Landscape of Non-Clear Cell Renal Cell Carcinoma: A Review of the Literature
John, A., Spain, L. A., & Hamid, A. (2023) · Current Oncology · doi:10.3390/curroncol30010070 · Cited by 19
“Moving forward, early results of HIF inhibitor trials have been promising, with the oral HIF-2 inhibitor Belzutifan inducing response rates of 49% in patients with VHLassociated RCC [87].”
BackgroundA View on Drug Development for Cancer Prevention
Reynolds, A. R., Moschetta, M., Yohannes, A. R., Walcott, F. L., Ashford, M. B., Szűcs, Z., Sarbajna, T., Hadfield, J., Harrison, E., Challis, B., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0776 · Cited by 21
Cotton, C. C., Chandrabhatla, A. S., Andrews, P. H., Purow, B. W., & Shildkrot, Y. (2023) · Retinal Cases & Brief Reports · doi:10.1097/icb.0000000000001516 · Cited by 19
Agarwal, N., Brugarolas, J., Ghatalia, P., George, S., Haanen, J. B. A. G., Gurney, H., Ravilla, R., Veldt, A. A. M. V. D., Beuselinck, B., Покатаев, И. А., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.08.2338 · Cited by 19
Self-citationPal, S. K., Bernard‐Tessier, A., Grell, P., Gao, X., Kotecha, R. R., Picus, J., de Braud, F., Takahashi, S., Wong, A. S. C., Suárez, C., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-2618 · Cited by 18
“Belzutifan, an allosteric inhibitor of HIF-2 α , was first approved for use in patients with germline VHL alterations demonstrating elements of VHL syndrome (3).”
Chatzopoulos, K., Aubry, M.-C., & Gupta, S. (2022) · Human Pathology · doi:10.1016/j.humpath.2022.02.009 · Cited by 18
Iacovelli, R., Arduini, D., Ciccarese, C., Pierconti, F., Strusi, A., Piro, G., Carbone, C., Foschi, N., Daniele, G., & Tortora, G. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103750 · Cited by 18
Therapy Resistant Gastroenteropancreatic Neuroendocrine Tumors
McClellan, K. V., Chen, E. Y.-S., Kardosh, A., Lopez, C. D., Rivero, J. D., Mallak, N., Rocha, F. G., Koethe, Y., Pommier, R. F., Mittra, E., et al. (2022) · Cancers · doi:10.3390/cancers14194769 · Cited by 20
“This study demonstrated that the use of belzutifan resulted in a 49% objective response for their RCC as well as a 77% response in those patients with synchronous with panNETs [76].”
MethodHIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans
Ma, Y., Joyce, A., Brandenburg, O., Saatchi, F., Stevens, C., Tcheuyap, V. T., Christie, A. L., Do, Q. N., Fatunde, O., Macchiaroli, A., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0963 · Cited by 21
Suárez, C., Vieito, M., Valdivia, A., González, M., & Carles, J. (2023) · Medical Sciences · doi:10.3390/medsci11030046 · Cited by 21
“This clinical trial’s main purpose was to evaluate Belzutifan’s safety and efficacy in patients with VHL-associated renal cell carcinoma and other VHL-disease-associated tumors [37].”
BackgroundNeth, B. J., Webb, M., White, J. B., Uhm, J. H., Pichurin, P. N., & Sener, U. T. (2023) · Journal of Neuro-Oncology · doi:10.1007/s11060-023-04395-3 · Cited by 18
Clinically significant germline pathogenic variants are missed by tumor genomic sequencing
Stout, L. A., Hunter, C., Schroeder, C., Kassem, N., & Schneider, B. P. (2023) · npj Genomic Medicine · doi:10.1038/s41525-023-00374-9 · Cited by 18
“Increasingly, germline PVs serve not only as a predictor of cancer risk but also may predict bene fi t to speci fi c targeted agents such as PARP-inhibition for patients with speci fi c tumors who harbor PVs in the homologous recombination genes and belzutifan for those with germline VHL PVs 3 .”
Hereditary Syndromes Associated with Pancreatic and Lung Neuroendocrine Tumors
Papadopoulou‐Marketou, N., Tsoli, M., Chatzellis, E., Alexandraki, K., & Kaltsas, G. (2024) · Cancers · doi:10.3390/cancers16112075 · Cited by 22
“A phase II clinical trial including 61 patients with VHL, showed an objective response rate of 49% and 30% for RCC and CNS hemangioblastomas [98].”
BackgroundSingle-Molecule SERS Discrimination of Proline from Hydroxyproline Assisted by a Deep Learning Model
Zhao, Y., Zhan, K., Xin, P.-L., Chen, Z., Li, S., Angelis, F. D., & Huang, J. (2025) · Nano Letters · doi:10.1021/acs.nanolett.5c01177 · Cited by 18
Metastasis prevention: targeting causes and roots
Schegoleva, A. A., Khozyainova, A. A., Gerashchenko, T. S., Zhuikova, L. D., & Denisov, E. V. (2022) · Clinical & Experimental Metastasis · doi:10.1007/s10585-022-10162-x · Cited by 19
Rapid Cardiovascular Response to Belzutifan in HIF2A -Mediated Paraganglioma
Alkaissi, H. R., Nazari, M. A., Vanova, K. H., Uher, O., Gordon, C. M., Talvacchio, S. K., Diachenko, N., Mukvich, O. M., Wang, H., Glod, J. W., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmc2409427 · Cited by 17
Molecular Genetics of Renal Cell Carcinoma: A Narrative Review Focused on Clinical Relevance
Millan, B., Loebach, L., Blachman-Braun, R., Patel, M. H., Saini, J., Linehan, W. M., & Ball, M. W. (2025) · Current Oncology · doi:10.3390/curroncol32060359 · Cited by 17
Self-citationWang, B., Xiang, Y., Liu, X., Pan, X., Peng, L., & Ma, J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1582887 · Cited by 18
“Tumor-in fi ltrating lymphocytes (TILs) represent a promising adoptive cell therapy, especially for immunogenic tumors like metastatic melanoma, where clinical studies report an ORR of 49 72% and complete response (CR) rates of 10-20%, with approximately 40% achieving durable responses (78, 79).”
InfluentialJones, A. A., Schloemer, N. J., & Wirostko, W. J. (2023) · Retinal Cases & Brief Reports · doi:10.1097/icb.0000000000001452 · Cited by 17
Population pharmacokinetic analyses for belzutifan to inform dosing considerations and labeling
Marathe, D. D., Jauslin, P. M., Kleijn, H. J., Silva, C. D. M., Chain, A. S. Y., Bateman, T. J., Shaw, P. M., Abraham, A. K., Kauh, E. A., Liu, Y., et al. (2023) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.13028 · Cited by 17
Self-citationDaffern, N., & Radhakrishnan, I. (2023) · Journal of Molecular Biology · doi:10.1016/j.jmb.2023.168370 · Cited by 18
Cumulative Impact of Serial Partial Nephrectomy for the Treatment of Recurrent Renal Masses
Antony, M. B., Kozel, Z., Gopal, N., Loebach, L., Metwalli, A. R., Gurram, S., Linehan, W. M., & Ball, M. W. (2024) · The Journal of Urology · doi:10.1097/ju.0000000000004099 · Cited by 17
Self-citationBiomarker-informed care for patients with renal cell carcinoma
Mckinnon, M., Rini, B. I., & Haake, S. M. (2025) · Nature Cancer · doi:10.1038/s43018-025-00942-1 · Cited by 19
“The HIF2 inhibitor belzutifan was first tested in patients with VHL syndrome and RCC 89 .”
Dhawan, A., Peereboom, D. M., & Stevens, G. H. J. (2022) · CNS Oncology · doi:10.2217/cns-2022-0008 · Cited by 16
Rizzo, M., Pezzicoli, G., Santoni, M., Caliò, A., Martignoni, G., & Porta, C. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188823 · Cited by 16
Personalized Systemic Therapies in Hereditary Cancer Syndromes
Mastrodomenico, L., Piombino, C., Riccò, B., Barbieri, E., Venturelli, M., Piacentini, F., Dominici, M., Cortesi, L., & Toss, A. (2023) · Genes · doi:10.3390/genes14030684 · Cited by 17
“The approval was based on a phase II open label single-group trial [168] of 61 patients with VHL-associated RCC, with a VHL germline variant and with at least one measurable solid tumor localized to the kidney.”
MethodSemenescu, L. E., Kamel, A., Ciubotaru, V. G., Rodriguez, S. M. B., Fürtös, A. M., Costachi, A., Dricu, A., & Tătăranu, L. G. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45090485 · Cited by 18
“A rising number of systemic therapies are being developed for mRCC, including immune checkpoint inhibitors (ICIs), which have also been studied in patients with BM RCC [11].”
BackgroundOxygen‐sensing pathways and the pulmonary circulation
Slingo, M. (2023) · The Journal of Physiology · doi:10.1113/jp284591 · Cited by 16
A Phase 2 Trial of Talazoparib and Avelumab in Genomically Defined Metastatic Kidney Cancer
Kotecha, R. R., Doshi, S. D., Knežević, A., Chaim, J. L., Chen, Y., Jacobi, R., Zucker, M. R., Reznik, E., McHugh, D. J., Shah, N. J., et al. (2023) · European Urology Oncology · doi:10.1016/j.euo.2023.10.017 · Cited by 19
Belzutifan-induced regression of retinal capillary hemangioblastoma: A case-series
Ercanbrack, C. W., Elhusseiny, A. M., Sanders, R. N., Horta, E. S., & Uwaydat, S. H. (2024) · American Journal of Ophthalmology Case Reports · doi:10.1016/j.ajoc.2024.102011 · Cited by 16
Guo, W., Hoque, J., García, C. J. G., Spiller, K. V., Leinroth, A. P., Puviindran, V., Potnis, C., Gunn, K. A., Newman, H., Ishikawa, K., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abo5217 · Cited by 16
“Systemic administration of such compounds has led to adverse events, particularly anemia, caused by the reduction of circulating erythopoietin (EPO) due to renal HIF-2α inhibition that can contribute to dose-limiting toxicities ( 28 , 29 ).”
BackgroundInfluentialSystemic therapy for patients with metastatic pheochromocytoma and paraganglioma
Fischer, A., Rivero, J. D., Wang, K., Nölting, S., & Jiménez, C. (2025) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2025.101977 · Cited by 15
Schweickert, P. G., Piovesan, D., Mitchell, C. G., Zepeda‐Carranza, B., Zhu, W. S., Espinoza, A. Y. L., Rocha, L., Singh, J., Malgapo, M. I. P., Meleza, C., et al. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70075 · Cited by 17
“…inhibitor, belzutifan (MK-6482/PT2977), featuring improved potency and PK properties (Xu et al., 2019) that is now approved for the treatment of adult patients with pheochromocytoma or paraganglioma (FDA, 2025), advanced RCC (Choueiri et al., 2024) and VHL disease (Jonasch et al., 2021).”
Research highlights of clinical oncology early 2022
Wu, K. (2022) · Holistic Integrative Oncology · doi:10.1007/s44178-022-00006-9 · Cited by 16
BNIP3 Upregulation Characterizes Cancer Cell Subpopulation With Increased Fitness and Proliferation
Zhu, Y., Chen, B., Yan, J., Zhao, W., Dou, P., Sun, N., Wang, Y., & Huang, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.923890 · Cited by 15
“Targeting HIF-2a with belzutifan (MK-6482) has been quite successful in a recent phase II trial, achieving a 49% objective response rate in patients with renal cell carcinoma (19).”
BackgroundLauricella, E., Mandriani, B., Cavallo, F., Pezzicoli, G., Chaoul, N., Porta, C., & Cives, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.957068 · Cited by 15
“Belzutifan (68) HIF-2a Open-label phase 2 study Advanced panNENs arising in the context of VHL syndrome 22 – Anemia (8%)* Hypertension (8%)* Fatigue (5%)*”
BackgroundCinque, A., Minnei, R., Floris, M., & Trevisani, F. (2022) · Cancers · doi:10.3390/cancers14215352 · Cited by 17
“Belzutifan approval is based on the NCT03401788 trial, which included individuals with renal masses ranging from 10 to 61mm with no evidence of metastatic disease [102].”
Multi-level interaction between HIF and AHR transcriptional pathways in kidney carcinoma
Lafleur, V. N., Halim, S., Choudhry, H., Ratcliffe, P. J., & Mole, D. R. (2023) · Life Science Alliance · doi:10.26508/lsa.202201756 · Cited by 16
“The fi rst HIF-2 dimerization inhibitor (belzutifan/PT2977) has recently been approved by the US Food and Drug Administration for the treatment of ccRCC in patients with the familial VHL syndrome (14, 35).”
Zuo, Q., Yang, Y., Lyu, Y., Yang, C. G., Chen, C. O., Salman, S., Huang, T. Y.-T., Wicks, E. E., Jackson, W., Datan, E., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112164 · Cited by 15
Neurocutaneous Diseases: Diagnosis, Management, and Treatment
Kioutchoukova, I. P., Foster, D. T., Thakkar, R. N., Ciesla, C. D., Cabassa, J. S., Strouse, J., Kurz, H., & Lucke-Wold, B. P. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13061648 · Cited by 15
“It is an inhibitor of HIF-2 α and has been very effective in treatment [95].”
BackgroundA patent review on hypoxia-inducible factor (HIF) modulators (2021–2023)
Liu, J., Gao, Y., & Zhang, X. (2024) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2024.2368739 · Cited by 16
“Interestingly, the incidence of anemia was low in patients who received administration of inhibitors of the vascular growth factor receptor (VEGFR) [87–89].”
Fitzgerald, K. N., & Lee, C. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.7003 · Cited by 15
“28 Genetic testing can also help fi rst-line therapy selection if it leads to clari fi cation of RCC histologic subtype.”
BackgroundHow the histological structure of some lung cancers shaped almost 70 years of radiobiology
Worth, K. R., Papandreou, I., & Hammond, E. M. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-02041-9 · Cited by 15
“Despite this, an oral inhibitor of HIF-2α (belzutifan) was recently FDA approved in 2021 for use in patients with Von Hippel–Lindau disease-associated cancers such as renal cell carcinoma following promising results from a Phase II trial (NCT03401788) [43].”
BackgroundUpdate on Surveillance in Von Hippel–Lindau Disease
Rednam, S. P., Becktell, K. D., Villani, A., Brodeur, G. M., States, L. J., Doria, A. S., Kamihara, J., Schneider, K. W., Voss, S. D., Widjaja, E., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-3525 · Cited by 15
Alkaissi, H. R., Talvacchio, S. K., Derkyi, A., Gubbi, S., Pappo, A. S., Gordon, C. M., Glod, J. W., Zhuang, Z., & Pacák, K. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.09.204 · Cited by 15
Santoni, M., Molina‐Cerrillo, J., Santoni, G., Lam, E. T., Massari, F., Mollica, V., Mazzaschi, G., Rapoport, B. L., Grande, E., & Buti, S. (2023) · Cancers · doi:10.3390/cancers15020408 · Cited by 13
“Recently, the role of HIF as a potential therapeutic target in RCC patients has been supported by the positive results obtained by Belzutifan (MK-6482), a potent selective small molecule inhibitor of the HIF-2α subunit [31].”
BackgroundZamarud, A., Marianayagam, N. J., Park, D. J., Yener, U., Yoo, K. H., Meola, A., & Chang, S. D. (2023) · Journal of Neuro-Oncology · doi:10.1007/s11060-023-04496-z · Cited by 14
“Belzutifan, a Hypoxia Inducible Factor 2-alpha (HIF 2a) inhibitor [ 16, 17], was approved by the FDA in 2021 for the treatment of renal cell carcinoma (RCC) in patients with Von-Hippel Landau (VHL) disease [ 7 – 9 , 17 ].”
InfluentialGenomic alterations and diagnosis of renal cancer
Zhang, X., Bolck, H. A., Rupp, N. J., & Moch, H. (2023) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-023-03700-9 · Cited by 15
“Most importantly, novel therapies for renal cancer have been developed targeting the VHL-HIF pathway; thus, broad profiling of VHL aberrations may open the possibility to administer these drugs to a wide range of patients [43–45].”
BackgroundLarcher, A., Belladelli, F., Cei, F., Re, C., Rowe, I., Montorsi, F., Umberto Capitanio, A., & Salonia, A. (2024) · Nature Reviews Urology · doi:10.1038/s41585-024-00874-y · Cited by 16
Jamshidi, F., Lozano, L. P., Tucker, B., Andorf, J., Sohn, E. H., Stone, E. M., Groves, A. P., Zakharia, Y., Boldt, H. C., & Binkley, E. M. (2024) · Ocular Oncology and Pathology · doi:10.1159/000539434 · Cited by 14
Zhu, Y., Li, Y., Li, X., Yu, Y., Zhang, L., Zhang, H., Chen, C., Chen, D., Wang, M., Xing, N., et al. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202402973 · Cited by 16
Model systems in SDHx-related pheochromocytoma/paraganglioma
Takács‐Vellai, K., Farkas, Z., Ősz, F., & Stewart, G. W. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-10009-z · Cited by 16
Trac, N. T., Oh, H. S., Jones, L. I., Caliliw, R., Ohtake, S., Shuch, B. M., & Chung, E. J. (2022) · Molecules · doi:10.3390/molecules27238457 · Cited by 14
Associations between HIFs and tumor immune checkpoints: mechanism and therapy
Liu, J., Jiang, Y., Chen, L., Qian, Z., & Zhang, Y. (2024) · Discover Oncology · doi:10.1007/s12672-023-00836-7 · Cited by 13
Molecular and therapeutic landscape of non-clear cell renal carcinoma
Nepali, P. R., Eraky, A., Okhawere, K. E., Dogra, N., Mehrazin, R., Badani, K. K., & Kyprianou, N. (2025) · Nature Reviews Urology · doi:10.1038/s41585-025-01056-0 · Cited by 15
“In patients with VHL-associated RCC, belzutifan treatment resulted in a 49% ORR and a disease control rate of 92% 206,207 .”
Yang, J., Miao, D., Li, X., Zhao, C., Tan, D., Wu, S., Lu, F., Shi, J., Lv, Q., Ruan, H., et al. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1664292 · Cited by 15
Targeting of HIF2-driven cachexia in kidney cancer
Abu‐Remaileh, M., Stransky, L. A., Bhalerao, N., Shirole, N. H., Jiang, Q., Saad, E., Machaalani, M., Vigeant, S. M., Woldemichael, H. B., Xu, C., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-04054-2 · Cited by 15
“The first of these, belzutifan (Welireg), is now approved for the treat-ment of sporadic ccRCCs and tumors arising in patients with germline VHL mutations (VHL disease) 10,11 .”
In Vitro and In Silico Evaluation of Red Algae Laurencia obtusa Anticancer Activity
Monteiro, J. R. B., Rodrigues, R. P., Mazzuco, A. C. D. A., Gonçalves, R. D. C. R., Bernardino, A. F., Kuster, R. M., & Kitagawa, R. R. (2023) · Marine Drugs · doi:10.3390/md21060318 · Cited by 13
“The MK-6482 (previously named PT2977) binds to HIF-2α and creates a steric hindrance that interrupts its dimerization with ARNT, inhibiting its transcriptional activity [15,16,38,39].”
BackgroundMohindroo, C., Baydogan, S., Agarwal, P., Wright, R. D., Prakash, L. R., Mork, M. E., Klein, A. P., Laheru, D. A., Maxwell, J. E., Katz, M. H. G., et al. (2024) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-23-0483 · Cited by 15
Stransky, L. A., Gao, W., Schmidt, L. S., Bi, K., Ricketts, C. J., Ramesh, V., James, A. E., Difilippantonio, S., Ileva, L. V., Kalen, J. D., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2408549121 · Cited by 12
Self-citationWang, Y., Song, J., Zheng, S., & Wang, S. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.102193 · Cited by 13
Metadata
- Authors
- Jonasch, E., Donskov, F., Iliopoulos, O., Rathmell, W. K., Narayan, V. K., Maughan, B. L., Oudard, S., Else, T., Maranchie, J. K., Welsh, S. J., Thamake, S., Park, E. K., Perini, R. F., Linehan, W. M., & Srinivasan, R.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- From the University of Texas M.D. Anderson Cancer Center, Houston (E.J.); Aarhus University Hospital, Aarhus, Denmark (F.D.); Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston (O.I.); Vanderbilt University Medical Center, Nashville (W.K.R.); University of Pennsylvania, Philadelphia (V.K.N.); the University of Utah, Salt Lake City (B.L.M.); Hôpital Européen Georges-Pompidou, University of Paris, Paris (S.O.); the University of Michigan, Ann Arbor (T.E.); the University of Pittsburgh, Pittsburgh (J.K.M.); Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom (S.J.W.); Merck, Kenilworth, NJ (S.T., E.K.P., R.F.P.); and the Center for Cancer Research, National Cancer Institute, Bethesda, MD (W.M.L., R.S.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-11-25
- Volume
- 385
- Issue
- 22
- Pages
- 2036-2046
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC9275515
- OpenAlex
- W3215189579
- Cited by
- 714
- References
- 22
- Citations by year
- 2026: 140 · 2025: 167 · 2024: 135 · 2023: 140 · 2022: 128 · 2021: 4
- FWCI
- 66.14
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA
- Topics
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Ear and Head Tumors
- Keywords
- belzutifan, HIF-2α inhibition, von Hippel-Lindau disease, renal cell carcinoma, hemangioblastoma, retinal hemangioblastoma, pancreatic lesions, anemia, drug safety, objective response
- MeSH terms
- Adult, Aged, Anemia, Antineoplastic Agents, Carcinoma, Renal Cell, Fatigue, Female, Follow-Up Studies, von Hippel-Lindau Disease, Humans, Indenes, Kidney Neoplasms, Male, Middle Aged, Neoplasms, Multiple Primary, Pancreatic Neoplasms, Age of Onset, Hemangioblastoma, Neuroendocrine Tumors, Disease Progression, Basic Helix-Loop-Helix Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
